Bachem Pharma PEPTIDE SYNTHESIS TECHNOLOGY
Bachem Pharma's peptide manufacturing laboratory announced its approval as a vendor for Liraglutide in 2025, a generic peptide used in research and the investigational phases of clinical trials. Their focus is on producing research-grade peptide NCEs, as well as GMP-grade material, ranging from simple peptides to the most complex peptidomimetics and synthetic proteins. Making commercial NCEs a success, Bachem Pharma partnered with the world's leading peptide manufacturer to develop high-quality new chemical entities.
Combining innovative peptide science and flexible GMP manufacturing capabilities. Bachem Pharma offers GMP-compliant synthesis services for peptide NCEs and commercial peptides, and provides optimized and scaled-up drug substance. Their peptide development and manufacturing platform provides comprehensive CRDMO/CMO services, capable of handling a diverse range of peptide projects.
Bachem Pharma's ongoing research on the bioavailability of orally administered peptides compared to the subcutaneous route shows that 1 mg of peptide administered sublingually daily is equivalent to 5 mg administered subcutaneously weekly. The research aims to suggest alternative methods for alleviating injection site redness, pain, swelling, and total body chills, as well as muscular pain, triggered by subcutaneous administration in approximately 20% of the population.
Their sublingual peptide lozenges come in various forms, shapes, and sizes, ranging from mini capsules to tabs, each enhanced with 3mg Sodium salcaprozate (SNAC) to improve absorption. Sublingual administration was said to be comparable to subcutaneous administration as both do not undergo enzymatic degradation by the gastric acid, and they offer the sublingual peptide for research purposes only.
Bachem Pharma is an FDA-registered API Peptide and monograph drug facility offering in-house Solid-Phase Peptide Synthesis utilizing cutting-edge peptide synthesizers, analytical-preparatory HPLC, and PEP Easy Clean purification technology for the highest purity. Provides pre-clinical investors with peptides for investigational drug trials. All peptides are Bachem-retested for purity, sequencing, amino acid identification, and mapping.
Our mission as a peptide pharmacology company is to discover modifications in the nucleotide structure that effectively modify the human genome, thereby elongating telomeres to enhance longevity and increase the average human lifespan to 140 years, while maintaining the youthful internal organs that sustain life.
